Effect of Dapagliflozin on Cause-Specific Mortality in Patients With Heart Failure Across the Spectrum of Ejection Fraction: A Participant-Level Pooled Analysis of DAPA-HF and DELIVER
JAMA Cardiol. 2022; online ahead of print DOI: 10.1001/jamacardio.2022.3736
The two trials, enrolling patients across the spectrum of EF, have previously shown that dapagliflozin reduces the rate of the composite of worsening HF events or death from CV causes compared with placebo. This analysis examined the effects of dapagliflozin on cause-specific CV and non-CV mortality across the spectrum of EF.
Rates of CV mortality – principally sudden death and HF death – were higher among HF patients with lower EF, whereas non-CV deaths were largely consistent across the EF spectrum. Across the full spectrum of EF, dapagliflozin significantly reduced risks of CV death with contributions from lower rates of sudden death and death from progressive HF.